Why the study?
Outcomes in AF patients undergoing percutaneous LAAO with concomitant HFpEF and HFrEF were not well determined.
Does concomitant heart failure (HFpEF or HFrEF) increase the risk of procedural complications, in-hospital mortality, or resource utilization in patients with atrial fibrillation undergoing percutaneous LAAO?
Does concomitant heart failure (HFpEF or HFrEF) increase the risk of procedural complications, in-hospital mortality, or resource utilization in patients with atrial fibrillation undergoing percutaneous LAAO?
Answers are grounded in this paper and cite their sources.
In patients with atrial fibrillation undergoing LAAO, concomitant heart failure is not independently associated with major procedural complications or in-hospital mortality, though it increases length of stay and costs.
AIMS: To determine outcomes in atrial fibrillation (AF) patients undergoing percutaneous left atrial appendage occlusion (LAAO) with concomitant heart failure with preserved ejection fraction (HFpEF) and heart failure with reduced ejection fraction (HFrEF). METHODS AND RESULTS: Data were extracted from National Inpatient Sample for calendar years 2015-2019. LAAO device implantations were identified on the basis of ICD-10-CM code of 02L73DK. The outcomes assessed in our study included complications, in-patient mortality, and resource utilization. A total of 62 980 LAAO device implantations were studied. HFpEF (14.4%, n = 9040) and HFrEF (11.2%, n = 7100) were associated with a higher prevalence of major complications and in-patient mortality in crude analysis. In the multivariate model adjusted for potential confounders, HFpEF and HFrEF were not associated with major complications [adjusted odds ratio (aOR) 1.04, 95% confidence interval (CI) 0.93-1.16 and aOR 1.07, 95% CI 0.95-1.21] or in-patient mortality (aOR 1.48, 95% CI 0.85-2.55 and aOR 1.26, 95% CI 0.67-2.38). HFpEF and HFrEF were associated with prolonged length of stay (LOS) > 1 day (aOR 1.41, 95% CI 1.31-1.53 and aOR 1.66, 95% CI 1.53-1.80) and increased hospitalization costs > median cost 24 752$ (aOR 1.26, 95% CI 1.19-1.34 and aOR 1.21, 95% CI 1.13-1.29). CONCLUSION: The prevalence of HF in AF patients undergoing percutaneous LAAO was approximately 26%. HF was not independently associated with major complications and in-patient mortality but was associated with prolonged LOS and higher hospitalization costs.
No takes yet. Share an insight, caveat, or question.
Munir et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: